Literature DB >> 1734047

Serotype prevalence of Candida albicans from blood culture isolates.

D L Brawner1, G L Anderson, K Y Yuen.   

Abstract

Blood culture isolates of Candida albicans were collected from 102 patients in Seattle, Wash., hospitals (n = 77) and Hong Kong (n = 25). The patients were classified by immune status into two groups. Group I patients were severely immunosppression, and group II patients had underlying risk factors for candidemia but no underlying immunosuppression. Serotyping by Hasenclever tube agglutination was done. In the Seattle area, the odds of fungemia with type B C. albicans were 3.62 times greater than the odds of type B fungemia in group II patients. Although the odds ratio could not be computed for Hong Kong patients, the direction of the relationship in this population was consistent with the data on Seattle patients. Despite the magnitude of the odds ratios, the relative prevalence of type B over type A in group I compared with group II was not significant when analyzed separately by region, probably because of relatively low numbers of isolates in group II. Accepting that the effect of immune status on serotype is equivalent across regions but presupposing that a regional effect on type B prevalence exists, the pooled odds for fungemia with serotype B in group I patients are increased 5.4-fold over those of group II patients. Logistic regression analysis controlling for region gave similar results.

Entities:  

Mesh:

Year:  1992        PMID: 1734047      PMCID: PMC265011          DOI: 10.1128/jcm.30.1.149-153.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Electrophoretic karyotyping of typical and atypical Candida albicans.

Authors:  M Mahrous; T J Lott; S A Meyer; A D Sawant; D G Ahearn
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

2.  Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States.

Authors:  R L Stiller; J E Bennett; H J Scholer; M Wall; A Polak; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

3.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy.

Authors:  R Horn; B Wong; T E Kiehn; D Armstrong
Journal:  Rev Infect Dis       Date:  1985 Sep-Oct

4.  Fungal infections in bone marrow transplant patients.

Authors:  J D Meyers
Journal:  Semin Oncol       Date:  1990-06       Impact factor: 4.929

5.  Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells.

Authors:  N Firon; S Ashkenazi; D Mirelman; I Ofek; N Sharon
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

6.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

7.  Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Diagnostic value of bacterial and fungal blood cultures in patients with the acquired immunodeficiency syndrome.

Authors:  S J Katz; N S Wenger; M F Shapiro
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

9.  Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain.

Authors:  W L Whelan; D R Kirsch; K J Kwon-Chung; S M Wahl; P D Smith
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

10.  Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype.

Authors:  D A Stevens; F C Odds; S Scherer
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr
View more
  7 in total

1.  Beta-1,2-mannosylation of Candida albicans mannoproteins and glycolipids differs with growth temperature and serotype.

Authors:  P A Trinel; T Jouault; J E Cutler; D Poulain
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

2.  Cell wall mannan and cell surface hydrophobicity in Candida albicans serotype A and B strains.

Authors:  James Masuoka; Kevin C Hazen
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Candida albicans serotype analysis by flow cytometry.

Authors:  S Mercure; S Sénéchal; P Auger; G Lemay; S Montplaisir
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  New method for detection of Candida albicans in human blood by polymerase chain reaction.

Authors:  Y Miyakawa; T Mabuchi; Y Fukazawa
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

5.  Epidemiological analysis of Candida albicans strains by multilocus enzyme electrophoresis.

Authors:  D A Caugant; P Sandven
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Biofilms of Candida albicans serotypes A and B differ in their sensitivity to photodynamic therapy.

Authors:  Rodnei Dennis Rossoni; Júnia Oliveira Barbosa; Felipe Eduardo de Oliveira; Luciane Dias de Oliveira; Antonio Olavo Cardoso Jorge; Juliana Campos Junqueira
Journal:  Lasers Med Sci       Date:  2014-04-12       Impact factor: 3.161

7.  Oropharyngeal candidosis relative frequency in radiotherapy patient for head and neck cancer.

Authors:  Hema Suryawanshi; Sindhu M Ganvir; Vinay K Hazarey; Varsha S Wanjare
Journal:  J Oral Maxillofac Pathol       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.